Mesenchymal Stem Cells Therapy for COVID-19: From Basic Research to Clinical Trial

Area of Science:

• Immunology
• Regenerative Medicine
• Virology

Background:

• Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes COVID-19, leading to severe respiratory distress and organ failure due to uncontrolled inflammation.
• Current COVID-19 treatments lack definitive cures, highlighting the need for novel therapeutic strategies targeting immune dysregulation.

Purpose of the Study:

• To elucidate the therapeutic mechanisms of mesenchymal stem cells (MSCs) in combating SARS-CoV-2 infection.
• To review and analyze recent clinical trials investigating MSCs as a treatment for severe and critical COVID-19.

Main Methods:

• Review of scientific literature on MSC immunomodulatory, anti-inflammatory, anti-apoptotic, and antiviral properties.
• Analysis of clinical trial data assessing MSC efficacy and safety in COVID-19 patients.

Main Results:

• MSCs exhibit multifaceted therapeutic potential through immune modulation and inflammation reduction.
• Clinical trials indicate MSCs may benefit severe COVID-19 cases, though further research is ongoing.

Conclusions:

• Mesenchymal stem cells represent a promising therapeutic avenue for severe COVID-19 by mitigating hyperinflammation and organ damage.
• Continued investigation into MSC-based therapies is crucial for optimizing treatment strategies against SARS-CoV-2.